Analyst Ratings January 27, 2026

Citizens Sticks With Market Outperform on Salesforce, Cites Rapid Agentforce Traction

Analyst maintains $405 price target as Agentforce ARR surpasses $500 million and enterprise adoption accelerates

By Sofia Navarro CRM
Citizens Sticks With Market Outperform on Salesforce, Cites Rapid Agentforce Traction
CRM

Citizens has reaffirmed its Market Outperform rating and a $405.00 price objective for salesforce.com (NYSE:CRM), pointing to substantial momentum in the company's Agentforce business and continued strong financial metrics. The target implies roughly 76% upside from recent trading levels, while third-party data indicates Salesforce is trading below its Fair Value. Citizens and other brokerages highlighted product adoption, enterprise use cases and management actions as pillars of confidence.

Key Points

  • Citizens reaffirmed a Market Outperform rating and a $405.00 price target on salesforce.com (NYSE:CRM), implying roughly 76% upside from a $229.40 share price.
  • Agentforce crossed $500 million in Annual Recurring Revenue in the fiscal third quarter and grew 330% year-over-year, with customers increasing consumption.
  • Strong financial metrics include 9% reported growth, a 35.5% non-GAAP operating margin in the fiscal third quarter of 2026, 77.73% gross profit margins, and $12.9 billion in levered free cash flow over the last twelve months - impacting enterprise software and cloud sectors.

Citizens has reiterated a Market Outperform rating on salesforce.com (NYSE:CRM) and kept a $405.00 price target, citing the rapid expansion of the company’s Agentforce offering as a primary driver of upside potential. At the current share price of $229.40, that target equates to about a 76% premium. Third-party InvestingPro data referenced by analysts indicates Salesforce is trading below its assessed Fair Value.

Agentforce momentum

The firm highlighted that Salesforce’s Agentforce business exceeded $500 million in Annual Recurring Revenue in the fiscal third quarter and recorded 330% year-over-year growth. Citizens noted that existing Agentforce customers have been returning to increase consumption of the service, an effect the firm described as customers coming back to "refill the tank."

Financial performance and margins

Salesforce reported 9% revenue growth and a 35.5% non-GAAP operating margin in its fiscal third quarter of 2026. Citizens pointed out that these results surpass the "Rule of 40" benchmark commonly used to assess software companies. InvestingPro figures cited in the analysis show gross profit margins of 77.73% and $12.9 billion in levered free cash flow generated over the trailing twelve months.

Customer traction and enterprise use cases

Checks conducted by Citizens with Salesforce partners revealed a robust demand picture and an active sales pipeline. The firm called out enterprise implementations including Olive, described as the AI Sous Chef for Williams Sonoma, and Pepsi, where Salesforce indicated Agentforce implementations have produced "massive efficiencies" in the range of 25-30%.

Management and capital allocation

Citizens expressed confidence in Salesforce’s executive team, referencing CEO Marc Benioff’s leadership, Chief Revenue Officer Miguel Milano’s enthusiasm and operational discipline from Chief Operating and Financial Officer Robin Washington. InvestingPro data included in the firm’s checks show management has been actively repurchasing shares and that the company carries a moderate level of debt while producing cash flows sufficient to cover interest payments.

Contracts and product rollouts

In other corporate developments mentioned by analysts, Salesforce has secured a $5.6 billion contract with the U.S. Army. The contract is structured as a 10-year Indefinite Delivery Indefinite Quantity (IDIQ) engagement and will be fulfilled by Computable Insights, a wholly owned Salesforce subsidiary. Separately, the company is rolling out a new AI-powered Slackbot aimed at helping enterprise customers complete work tasks more efficiently; availability is currently for Business+ and Enterprise+ customers with a phased rollout continuing through February.

Analyst community stance

Other sell-side firms have maintained bullish stances as well. KeyBanc reiterated an Overweight rating, citing opportunity in the Life Sciences Cloud market. Wolfe Research reaffirmed an Outperform rating after observing favorable momentum for Salesforce’s AI initiatives during the Agentforce World Tour in Boston. Cantor Fitzgerald kept an Overweight rating, noting Salesforce’s pursuit of a $60 billion revenue target by fiscal year 2030. Together, these ratings reflect continued analyst interest and confidence in Salesforce’s strategic trajectory.


Bottom line

Citizens’ reassertion of a Market Outperform rating and a $405.00 price target rests on rapid Agentforce growth, solid margin and cash-flow metrics, enterprise customer case studies and management’s capital deployment. InvestingPro data referenced by analysts signals a valuation gap relative to Fair Value, while recent product launches and the U.S. Army IDIQ contract add to the company’s set of growth catalysts.

Risks

  • Sustaining the high growth rate of Agentforce is uncertain and will affect enterprise software and cloud revenue trajectories.
  • Although management has repurchased shares and cash flows currently cover interest, the company operates with a moderate level of debt, creating potential balance-sheet and interest-coverage uncertainty for investors.
  • The Slackbot product is in a phased rollout through February; the staggered availability could delay broad adoption and any associated near-term revenue contribution for enterprise customers.

More from Analyst Ratings

Palantir Gains After Lofty 2026 Guidance; Analysts Split on Outlook Feb 2, 2026 Freedom Capital Markets Starts Coverage of Nebius Group With Buy Rating, $108 Target Feb 2, 2026 Clear Street Starts Coverage on Caribou Biosciences with Buy Rating and $13 Target Feb 2, 2026 Goldman Keeps OLN Neutral at $22 as Olin Signals Rough Q1, Cost Cuts to Cushion Results Feb 2, 2026 Aletheia Capital Starts Coverage on Teradyne With Buy Rating, $400 Target Feb 2, 2026